Lonza

Lonza is a leading CDMO for bioconjugates, supporting over 100 ADC programs since 2006. Our integrated offering spans from late discovery to commercial manufacturing, leveraging deep expertise across small molecules, mammalian and microbial systems, and bioconjugate drug candidates.

Through the acquisition of Synaffix and its clinical stage ADC technology platform, featuring GlycoConnect® bioconjugation technology, HydraSpace® polar spacer, and toxSYN® linker-payloads platform, Lonza enables the development of best-in-class antibody drug conjugates and other targeted therapeutics. These proprietary technologies support enhanced efficacy, tolerability, and rapid deployment for partners developing next generation bioconjugates.

With continued investment in large scale manufacturing, advanced conjugation technologies, and drug product filling, Lonza partners with biotechs and pharma companies to bring innovative therapies to patients efficiently, safely, and at scale.  Contact us and/or visit our website to find out more.